AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. They are a science leader with a mission to turn ideas into life-changing medicines that improve patients’ lives and benefit society. They are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia. In total, they employ over 59,000 people and invest over $4 billion in R&D each year.
Part of AstraZeneca’s contribution to the IMI project eTOX was in the form of extensive data on the safety/toxicity profiles of (potential) medicines. Now, the company has decided to make the data provided to eTOX available to the wider scientific community through the company’s Open Innovation portal.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research.
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.